.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The 2025 Bridging the Gaps Consensus Conference recently provided crucial updates on multiple myeloma management. A panel of 16 experts reviewed the latest clinical data to address existing gaps and therapeutic sequencing. Consequently, they developed 11 consensus recommendations spanning from smoldering disease to relapsed settings. Furthermore, these guidelines emphasize the integration of quadruplet induction and the strategic use of cellular therapies to improve outcomes.
The experts reached a strong consensus regarding the use of quadruplet regimens in the frontline setting. Specifically, adding a monoclonal antibody to the standard triplet backbone is now recommended for most patients. Additionally, the panel discussed the role of individualized maintenance therapy based on patient risk factors. However, they noted that the optimal duration of maintenance remains an area for further investigation. Moreover, early referral for CAR-T therapy is critical for patients experiencing early relapse. Therefore, hematologists should coordinate with transplant centers much sooner in the disease course.
Notably, the consensus highlights the growing importance of minimal residual disease (MRD) monitoring. Thus, MRD status may eventually guide treatment intensification or de-escalation decisions. Ultimately, these recommendations provide a practical roadmap for clinicians navigating the complex myeloma landscape. By standardizing care across different disease stages, the panel aims to improve long-term patient survival. Finally, ongoing research remains essential to refine these expert-derived pathways and address remaining controversies.
Quadruplet induction regimens, such as those combining a CD38-targeted antibody with a proteasome inhibitor and an immunomodulatory drug, offer higher rates of deep and durable responses compared to standard triplets.
Early referral ensures that patients with relapsed or refractory disease can access specialized cellular therapies before their clinical condition deteriorates, maximizing the potential for significant therapeutic benefit.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References
Chari A et al. Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference. Am J Hematol. 2026 Apr 21. doi: 10.1002/ajh.70339. PMID: 42014940.
Chari A, Bal S, Ailawadhi S, et al. Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2025 Sep;25(9):635-645. doi: 10.1016/j.clml.2025.03.008.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The 2025 Bridging the Gaps Conference offers 11 recommendations for multiple myeloma, focusing on quadruplet induction, maintenance, and CAR-T therapy....
6 months ago
Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today
A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
